The open reading frame L2 of cottontail rabbit papillomavirus contains antibody-inducing neutralizing epitopes

Christensen, Neil D.; Kreider, John W.; Kan, Nancy C.; DiAngelo, Susan

doi:10.1016/0042-6822(91)90890-n

Cited by 141 publications

(94 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is supported by recent reports showing that L2 proteins are accessible to antibody binding in complete virions (Yaegashi et al, 1991) and empty capsids (C. Volpers, M. Sapp, P. J. F. Snijders, J. M. M. Walboomers & R.E. Streeck, unpublished results) and, in addition, are able to induce neutralizing antibodies (Christensen et al, 1991;Roden et al, 1994).…”

Section: J M M W a L B O O M E R S And R E S T R E E C K U Nsupporting

confidence: 72%

Organization of the major and minor capsid proteins in human papillomavirus type 33 virus-like particles

Sapp¹,

Volpers²,

Müller

et al. 1995

Journal of General Virology

View full text Add to dashboard Cite

The organization of the major (L1) and minor (L2) proteins in the human papillomavirus capsid is still largely unknown. In this study we analysed the disulphide bonding between L1 proteins and the association of L2 proteins with capsomers using virus-like particles obtained in insect cells by co-expression of the L1 and L2 genes of human papillomavirus type 33. About 50% of the L1 protein molecules in these particles (1.29 g/cm z) formed disulphide-bonded trimers. Reduction of the intermolecular disulphide bonds by dithiothreitol (DTT) treatment caused disassembly of virus-like particles into capsomers. This indicates that disulphide bonds between capsomers at the threefold symmetry positions of the capsid are essential for the assembly of the papiUomavirus capsid. In contrast, the L2 protein was not engaged in intermolecular disulphide bonding. The L2 protein remained associated with capsomers on disassembly by treatment with DTT. When the disassembly was carried out in 0"65 u-NaC1, complete L2 protein molecules bound preferentially to capsomer oligomers, whereas truncated L2 protein molecules bound only to monomers. In 0.15 u-NaCl only complete L2 protein molecules remained bound to capsomers. This indicates that different regions of the L2 protein molecule are differentially involved in the association of the papillomavirus capsid.Papillomaviruses are a subfamily of the papovaviruses. The properties shared by these viruses include a circular dsDNA genome, a nonenveloped virion and an icosahedral capsid. Papillomaviruses have a specific tropism for epithelial cells and have been found in a great variety of species. More than 70 types of human papillomavirus (HPV) have been recognized but only a few, e.g. HPV-I (which induces cutaneous warts), can be isolated as virus particles. The other HPVs, e.g. HPV-16 or HPV-33 (which are associated with genital carcinoma), have only been identified by cloning their genomes from epithelial lesions. Moreover, no system exists for the efficient propagation of HPVs in vitro.

show abstract

Section: J M M W a L B O O M E R S And R E S T R E E C K U Nsupporting

confidence: 72%

Organization of the major and minor capsid proteins in human papillomavirus type 33 virus-like particles

Sapp¹,

Volpers²,

Müller

et al. 1995

Journal of General Virology

View full text Add to dashboard Cite

show abstract

“…Induction of neutralizing antibodies by immunization with L2 has been reported also for cottontail rabbit papillomavirus (CRPV; Christensen et al, 1991;Linet al, 1992). In those studies, removal of anti-L2 antibodies was not attempted and the neutralizing activity was mapped to the C-terminal half of CRPV L2 (Lin et al, 1992).…”

Section: Discussionmentioning

confidence: 99%

Vaccination of cattle with bovine papillomavirus type 4 L2 elicits the production of virus-neutralizing antibodies

Gaukroger¹,

Chandrachud²,

O’Neil³

et al. 1996

Journal of General Virology

View full text Add to dashboard Cite

“…Vaccination with the minor capsid protein L2 is protective in animal models [51][52][53] . Protection is mediated by neutralizing antibodies 54 , although the titres produced by L2 vaccination are much lower than for L1 VLP vaccines 55 .…”

Section: How To Overcome Type-restricted Protection?mentioning

confidence: 99%

How will HPV vaccines affect cervical cancer?

2006

View full text Add to dashboard Cite

Cancer of the uterine cervix is the second largest cause of cancer deaths in women, and its toll is greatest in populations that lack screening programmes to detect precursor lesions. Persistent infection with 'high risk' genotypes of human papillomavirus (HPV) is necessary, although not sufficient, to cause cervical carcinoma. Therefore, HPV vaccination provides an opportunity to profoundly affect cervical cancer incidence worldwide. A recently licensed HPV subunit vaccine protects women from a high proportion of precursor lesions of cervical carcinoma and most genital warts. Here we examine the ramifications and remaining questions that surround preventive HPV vaccines.Epidemiological and laboratory studies overwhelmingly support a necessary role for persistent human papillomavirus (HPV) infection and transcription in cervical carcinogenesis 1,2 (BOX 1). Importantly, HPV infection alone is not sufficient for cervical carcinogenesis, and additional steps occur over one or two decades. HPV is probably the most common sexually transmitted disease. It is estimated that the worldwide agestandardized prevalence of current HPV infection is 10.5% (95% CI 9.9-11.0) of women; the prevalence varies about 20-fold between different regions, from 1.4% (95% CI 0.5-2.2) in Spain to , although adenocarcinomas of the cervix are more challenging to detect with this approach. Progression to cancer can usually be prevented by the ablation or surgical removal of high-grade precursor lesions (HSIL or CIN2/3). In 2005, more than 60 million Pap smears were performed in the United States, and it is estimated that such screening programmes and intervention have reduced the incidence of cervical cancer by ~80% in the United States, but at a cost of more than US$6 billion a year.Despite this success, many women do not have access to screening. This problem is most acute in disadvantaged minorities in developed nations, in cultures that do not accept the screening process and in countries that are remote and lack the resources for screening programmes. Consequently, the impact of cervical cancer is greatest in these countries; the latest global estimates (from 2002) are 493,000 new cervical cancer cases each year, and 274,000 deaths, 80% of which occur in developing countries 8 .Vaccination traditionally represents the most cost-effective approach to combat infectious disease. Two approaches to vaccination, or a combination of both, can be considered: prophylactic (preventive) and therapeutic immunization. Prophylactic vaccination of healthy individuals against the aetiological agent protects against acquisition of the disease, but confers some risk to otherwise healthy patients and requires massive programmes to vaccinate a significant fraction of the population. Comprehensive prophylactic vaccination has historically proven most successful in disease reduction. The US Food and Drug Administration (FDA) approved a preventive HPV vaccine on 8 June 2006 for the immunization of women between 9-26 years of age 9 , and a second vacci...

show abstract

The open reading frame L2 of cottontail rabbit papillomavirus contains antibody-inducing neutralizing epitopes

Cited by 141 publications

References 24 publications

Organization of the major and minor capsid proteins in human papillomavirus type 33 virus-like particles

Organization of the major and minor capsid proteins in human papillomavirus type 33 virus-like particles

Vaccination of cattle with bovine papillomavirus type 4 L2 elicits the production of virus-neutralizing antibodies

How will HPV vaccines affect cervical cancer?

Contact Info

Product

Resources

About